Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Funding Amount
$19,100,000 total
Deadline
February 11, 2027
83 days left
Number of Awards
6
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Other requirements
- Other Eligible Applicants.
- For the NCTN Biobanks: Eligibility is limited to an institution/entity that is a recipient of an existing NCTN biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-002.
- For the EET Biobank: Eligibility is limited to the institution/entity that is a recipient of an existing EET biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-003.
Overview
Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of the two distinct biospecimen banking resources: The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), and The Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) support the Experimental Therapeutics Clinical Trials Network (ETCTN) and NCI-supported other early phase and experimental clinical trials. The objective is to maintain these robust national resources for continuing the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research. NCTN Biobanks support the biobanking operations of the NCTN funded through the Cancer Therapy Evaluation Program (CTEP) and NCORP funded through the Division of Cancer Prevention (DCP). The clinical trials conducted through NCTN and NCORP enroll thousands of patients with adult and childhood cancers each year. NCTN Biobank operations aim to facilitate hypothesis-driven biomarker development and validation, secondary research studies, and broader scientific discovery. Biospecimens collected through harmonized protocols and long-term follow-up across large multi-site clinical trials provide valuable resources for studying disease mechanisms, therapeutic response, and clinical outcomes in different types of cancers. This NOFO will also support the continuation of the EET Biobank, a dedicated resource with a primary focus on meeting the biospecimen banking needs of the ETCTN and other early-phase and experimental clinical trials involving investigational new drugs (INDs). Biospecimens collected
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-CA-25-035
- Total Funding: $19,100,000
- Expected Awards: 6
- Instrument: cooperative_agreement
Eligibility
Other Eligible ApplicantsFor the NCTN Biobanks: Eligibility is limited to an institution/entity that is a recipient of an existing NCTN biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-002. For the EET Biobank: Eligibility is limited to the institution/entity that is a recipient of an existing EET biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-003.
Focus Areas & Funding Uses
Fields of Work
- Cancer
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $375,000
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,400,000 total
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,000,000 total
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,500,000 total
Deadline
November 23, 2026
Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 24, 2026
Emerging Global Leader Award (K43 Independent Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
December 3, 2026
Ready to apply for Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed). Now let's win it.